Monday, the FDA issued complete response letters (CRL) to Regeneron Pharmaceuticals Inc’s REGN Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R)…
SOUTH SAN FRANCISCO, Calif. and BARCELONA, Spain, March 25, 2024 (GLOBE NEWSWIRE) — Verge Genomics, a leading clinical-stage biotechnology company,…
Thursday, Merck & Co Inc MRK released topline data from the Phase 3 KEYLYNK-006 trial evaluating Keytruda (pembrolizumab) in combination with maintenance…
An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy (GAN), that begins in early childhood…
Wednesday, the European Commission approved Bristol Myers Squibb & Co’s BMY Abecma (idecabtagene vicleucel; ide-cel) for relapsed and refractory multiple myeloma who…
Alzheimer’s disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline…
Saturday, GSK plc GSK announced overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase…
© Reuters. CAMBRIDGE, Mass. – Intellia Therapeutics, Inc. (NASDAQ:), a pioneer in gene editing treatments, has started its Phase 3…
The FDA granted accelerated approval on Thursday to Bristol Myers Squibb Co.’s BMY of Breyanzi (lisocabtagene maraleucel, liso-cel), a CD19-directed chimeric antigen…
Clinical-stage psychedelics biopharma company Cybin Inc. CYBN announced that the Food and Drug Administration has granted Breakthrough Therapy designation to…